Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk

Dow Jones

2025/11/03

0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com)

(END) Dow Jones Newswires

November 03, 2025 07:28 ET (12:28 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580229076"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580229076\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580229076?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580229076","market":"us","top_or_hot":-1,"title":"Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 07:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-03 20:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 07:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580229076","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580229076","pubTimestamp":1762172880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4588":"碎股","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4018":"居家用品","KMB":"金佰利","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","KVUE":"Kenvue Inc","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4504":"桥水持仓"},"translate_title":"在泰诺争议中，金佰利(Kimberly-Clark)在Kenvue上押注超过40B美元——市场讨论","themeId":"d7f4f57ff2cf212a4a46fa1f7ed8723f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KVUE":0.9,"KMB":1.5},"content_text":"0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 07:28 ET (12:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}